Adamas Announces New Employment Inducement Grant

Rhea-AI Summary

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced on December 11, 2020, that its compensation committee granted stock options and restricted stock units to two new employees. A total of 28,500 stock options were awarded, priced at $4.88 per share, alongside 14,250 restricted stock units. Both grants vest over four years and are issued under the 2016 Inducement Plan to attract new talent.

This initiative aims to enhance the company's ability to deliver innovative therapies for neurological diseases.

Positive

• Attracting new talent through stock options and restricted stock units.
• Alignment of employee interests with company performance.

Negative

• None.

EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the company’s common stock, at a per share exercise price of $4.88, the closing trading price on December 7, and restricted stock units to acquire 14,250 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc. 
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Contact:

Investors:
Peter Vozzo
Westwicke Partners
443-213-0505
peter.vozzo@westwicke.com

Media:
Sarah Mathieson
Vice President, Communications & Engagement
510-450-3528
smathieson@adamaspharma.com

FAQ

What did Adamas Pharmaceuticals announce on December 11, 2020 regarding employee stock options?

Adamas Pharmaceuticals announced the grant of stock options to two new employees, totaling 28,500 shares at an exercise price of $4.88.

How many restricted stock units were awarded by Adamas Pharmaceuticals?

The company awarded 14,250 restricted stock units to the new employees.

What is the vesting period for the stock options and restricted stock units granted by Adamas Pharmaceuticals?

The stock options and restricted stock units vest over a period of four years.

Under which plan did Adamas Pharmaceuticals grant the stock options and restricted stock units?

The grants were made under the Adamas Pharmaceuticals 2016 Inducement Plan.